These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20346655)

  • 1. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
    Fidanze SD; Erickson SA; Wang GT; Mantei R; Clark RF; Sorensen BK; Bamaung NY; Kovar P; Johnson EF; Swinger KK; Stewart KD; Zhang Q; Tucker LA; Pappano WN; Wilsbacher JL; Wang J; Sheppard GS; Bell RL; Davidsen SK; Hubbard RD
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2452-5. PubMed ID: 20346655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
    Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
    Renhowe PA; Pecchi S; Shafer CM; Machajewski TD; Jazan EM; Taylor C; Antonios-McCrea W; McBride CM; Frazier K; Wiesmann M; Lapointe GR; Feucht PH; Warne RL; Heise CC; Menezes D; Aardalen K; Ye H; He M; Le V; Vora J; Jansen JM; Wernette-Hammond ME; Harris AL
    J Med Chem; 2009 Jan; 52(2):278-92. PubMed ID: 19113866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.
    Lee KI; Park Y; Park SJ; Hwang JH; Lee SJ; Kim GD; Park WK; Lee S; Jeong D; Kong JY; Kang HK; Cho H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):737-42. PubMed ID: 16321529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
    Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
    Stieber F; Mazitschek R; Soric N; Giannis A; Waldmann H
    Angew Chem Int Ed Engl; 2002 Dec; 41(24):4757-61. PubMed ID: 12481350
    [No Abstract]   [Full Text] [Related]  

  • 11. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
    Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
    J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
    Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
    J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
    Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
    Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
    Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.
    Peifer C; Bühler S; Hauser D; Kinkel K; Totzke F; Schächtele C; Laufer S
    Eur J Med Chem; 2009 Apr; 44(4):1788-93. PubMed ID: 18524423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.